Author response: Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

There are some inconsistencies and misunderstandings in Dr. Avasarala’s analysis on the incidence of thyroid autoimmunity in patients with relapsing multiple sclerosis (RMS) treated with alemtuzumab.

Source link

Related posts

Serum elaidic acid concentration and risk of dementia: The Hisayama Study


Yoga Worth 'Serious Consideration' for Major Depression


Factorial validity and invariance of the Patient Health Questionnaire (PHQ)-9 among clinical and non-clinical populations.


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy